Injectable glucagon-like peptide-1 receptor agonists (GLP-1RA) are recent therapies found to be effective in treating dyslipidemia in diabetic patients by acting similarly to the body's internal glucagon peptide hormone, regulating blood sugar levels and reducing triglycerides and low-density lipoprotein (LDL) levels. Here, GLP1R is linked to metabolic syndrome.